Farichem Laboratories Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 31-07-2024
- Paid Up Capital ₹ 0.10 M
as on 31-07-2024
- Company Age 43 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 96.59%
(FY 2023)
- Profit 1582.28%
(FY 2023)
- Ebitda 1677.94%
(FY 2023)
- Net Worth 3306.56%
(FY 2023)
- Total Assets 60.03%
(FY 2023)
About Farichem Laboratories
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Surendra Jangir, Kalpana Umakanth, and Prabhudas Gohil serve as directors at the Company.
- CIN/LLPIN
U74110MH1981PTC024819
- Company No.
024819
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jul 1981
- Date of AGM
28 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Farichem Laboratories?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surendra Jangir  | Director | 09-Jun-2003 | Current |
| Kalpana Umakanth | Director | 15-Apr-2013 | Current |
| Prabhudas Gohil | Director | 15-Jan-1992 | Current |
Financial Performance of Farichem Laboratories.
Farichem Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 96.59% increase. The company also saw a substantial improvement in profitability, with a 1582.28% increase in profit. The company's net worth Soared by an impressive increase of 3306.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Farichem Laboratories?
In 2023, Farichem Laboratories had a promoter holding of 99.90% and a public holding of 0.10%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Walter Bushnell Medicines Private LimitedActive 17 years 6 monthsSurendra Jangir is a mutual person
Walter Bushnell Lifescience Private LimitedActive 2 years 10 monthsKalpana Umakanth and Prabhudas Gohil are mutual person
Walter Bushnell Pharmaceuticals Private LimitedActive 20 years 1 monthSurendra Jangir is a mutual person
Walter Bushnell Healthsciences Private LimitedActive 17 years 6 monthsPrabhudas Gohil is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Farichem Laboratories?
Unlock and access historical data on people associated with Farichem Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Farichem Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Farichem Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
